Zheng Li

Dr. Zheng Li

Jiangsu Normal University, Xuzhou, China
orcid
College of Health Sciences, School of Life Sciences, Jiangsu...

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Hongwei ChenHongwei Chen
Hongwei Chen
JWJue Wang
Jue Wang
ZLZheng Li
Zheng Li
CLChristopher Wai Kei Lam
Christopher Wai Kei Lam
YXYing Xiao
Ying Xiao
WZWei Zhang
Wei Zhang
Background: Non-alcoholic fatty liver disease (NAFLD) is a serious health problem, but the dose-response relationship between sugar-sweetened beverages (SSBs) and NAFLD remains uncertain. Methods: A systematic review and dose-response meta-analysis were conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Review Manager 5.3 and Stata 14.0 were used to combine trials and analyze data. The dose-response meta-analysis was performed by non-linear trend regression. Results: Twelve studies recruiting a total of 35,705 participants were included. The results showed that the consumption of SSBs was associated with 1.39-fold increased odds of NAFLD (95% CI: 1.29–1.50, p < 0.00001). The risk of NAFLD rose with an increased consumption of SSBs, while the consumptions of low doses (<1 cup/week), middle doses (1–6 cups/week) and high doses (≥7 cups/week) of SSBs increased the relative risk of NAFLD by 14%, 26% and 53%, respectively (p = 0.01, p < 0.00001, p = 0.03, respectively). Conclusions: This study demonstrates that consumers of SSBs are at significantly increased risk of NAFLD, and the consumption of SSBs has a dose-dependent effect on the risk of NAFLD. The findings of this study strengthen the evidence base for healthy dietary patterns and are meaningful for the primary prevention of NAFLD.

14 June 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
ZLZheng Li
Zheng Li
YLYan Li
Yan Li
HZHui‐Xia Zhang
Hui‐Xia Zhang
JGJian‐Ru Guo
Jian‐Ru Guo
CLChristopher Wai Kei Lam
Christopher Wai Kei Lam
WZWei Zhang
Wei Zhang

1 April 2020 in Phytomedicine
Verified
Journal Article
Closed access
ZLZheng Li
Zheng Li
HZHuixia Zhang
Huixia Zhang
YLYan Li
Yan Li
Hongwei ChenHongwei Chen
Hongwei Chen
CWCaiyun Wang
Caiyun Wang
WZWei Zhang
Wei Zhang

1 November 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SJShuai Ji
Shuai Ji
DHDan-Dan He
Dan-Dan He
TWTian-Yun Wang
Tian-Yun Wang
JHJie Han
Jie Han
ZLZheng Li
Zheng Li
DTDaoQuan Tang
DaoQuan Tang

19 January 2016 in Journal of Separation Science
Verified
Journal Article
Closed access
ZLZheng Li
Zheng Li
KCKai Chen
Kai Chen
MGMeng‐Zhe Guo
Meng‐Zhe Guo
DTDaoQuan Tang
DaoQuan Tang

21 March 2017 in Molecules
Verified
Journal Article
Open access
PDF file
ZLZheng Li
Zheng Li
JGJian-Ru Guo
Jian-Ru Guo
QCQian-Qian Chen
Qian-Qian Chen
CWCai-Yun Wang
Cai-Yun Wang
WZWei-Jia Zhang
Wei-Jia Zhang
WZWei Zhang
Wei Zhang
Despite the apparent clinical benefits of high-dose cytarabine (Ara-C) over lower dose Ara-C in acute myeloid leukemia (AML) therapy, the mechanism behind high-dose Ara-C therapy remains uncertain. In this study, a LC-MS-based method was carried out to investigate the metabolic alteration of ribonucleotide and deoxyribonucleotide in human promyelocytic leukemia cells (HL-60) after treatment with Ara-C to reveal its antitumor mechanism. The metabolic results revealed that four nucleotides (ATP, ADP, CDP, and dCTP) could be used as potential biomarkers indicating the benefit of high-dose Ara-C over lower dose Ara-C treatment. Combining metabolic perturbation and cell cycle analysis, we conjectured that, apart from the acknowledged mechanism of Ara-C on tumor inhibition, high-dose Ara-C could present a specific action pathway. It was suggested that the pronounced rise in AMP/ATP ratio induced by high-dose Ara-C can trigger AMP-activated protein kinase (AMPK) and subsequently Forkhead Box, class O (FoxO), to promote cell cycle arrest. Moreover, the significant decrease in CDP pool induced by high-dose Ara-C might further accelerate the reduction of dCTP, which then aggravates DNA synthesis disturbance. As a result, all of these alterations led to heightened tumor inhibition. This study provides new insight in the investigation of potential mechanisms in the clinical benefits of high-dose Ara-C in therapy for AML.